Compare · A vs ALMR
A vs ALMR
Side-by-side comparison of Agilent Technologies Inc. (A) and Alamar Biosciences Inc. (ALMR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both A and ALMR operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- A is the larger of the two at $43.71B, about 19.1x ALMR ($2.29B).
- Over the past year, A is up 30.8% and ALMR is up 48.6% - ALMR leads by 17.8 points.
- ALMR has hit the wire 5 times in the past 4 weeks while A has been quiet.
- A has more recent analyst coverage (25 ratings vs 5 for ALMR).
- Company
- Agilent Technologies Inc.
- Alamar Biosciences Inc.
- Price
- -
- -
- Market cap
- $43.71B
- $2.29B
- 1M return
- +12.18%
- +35.37%
- 1Y return
- +30.85%
- +48.64%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1999
- 2026
- News (4w)
- 0
- 5
- Recent ratings
- 25
- 5
Agilent Technologies Inc.
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid and gas chromatography systems and components; liquid and gas chromatography mass spectrometry systems; inductively coupled plasma mass and optical emission spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate readers; laboratory software, information management, and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment, genetic data management, and interpretation support software; and equipment to produce synthesized oligonucleotide. It also offers immunohistochemistry, in situ hybridization, and hematoxylin and eosin staining and special staining; instruments, consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. It has collaboration agreement with SGS AXYS. The company was incorporated in 1999 and is headquartered in Santa Clara, California.
Latest A
- Agilent Research Catalyst Award Presented to Eastern Institute of Technology, Ningbo
- Agilent to Announce Third-Quarter Fiscal Year 2026 Financial Results on Aug. 26
- Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
- Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma
- Jefferies resumed coverage on Agilent with a new price target
- Agilent Expands Altura Portfolio with Inert Size Exclusion and PLRP-S Columns for Biotherapeutic Analysis
- Agilent Launches AI-Driven Analysis Module for Agilent xCELLigence RTCA eSight
- Senior Vice President Kirkwood Jonah Prevost covered exercise/tax liability with 30 shares, decreasing direct ownership by 0.21% to 14,108 units (SEC Form 4)
- Bernstein resumed coverage on Agilent with a new price target
- Agilent Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
Latest ALMR
- SEC Form SCHEDULE 13G filed by Alamar Biosciences Inc.
- SEC Form 10-Q filed by Alamar Biosciences Inc.
- Alamar Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Alamar Biosciences Reports Second Quarter 2026 Financial Results and Provides 2026 Revenue Guidance
- Alamar Biosciences Expands Global Partnership with Alzheimer’s Disease Data Initiative and Gates Ventures
- Alamar Biosciences Launches NULISAseq™ Immune 340 Panel for Comprehensive Profiling of the Immune Proteome
- SEC Form 8-K filed by Alamar Biosciences Inc.
- Alamar Biosciences to Report Second Quarter 2026 Financial Results on August 10, 2026
- Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases
- Amendment: SEC Form SCHEDULE 13D/A filed by Alamar Biosciences Inc.